167 related articles for article (PubMed ID: 17460705)
1. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
Tefferi A; Lasho TL; Mesa RA; Pardanani A; Ketterling RP; Hanson CA
Leukemia; 2007 Aug; 21(8):1827-8. PubMed ID: 17460705
[No Abstract] [Full Text] [Related]
2. Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Lancet JE; List AF; Moscinski LC
Leukemia; 2007 Mar; 21(3):586-8. PubMed ID: 17230228
[No Abstract] [Full Text] [Related]
3. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
[No Abstract] [Full Text] [Related]
4. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
Mesa RA; Tefferi A; Li CY; Steensma DP
Leukemia; 2006 Nov; 20(11):2063-4. PubMed ID: 16990762
[No Abstract] [Full Text] [Related]
5. Thalidomide and lenalidomide in primary myelofibrosis.
Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
[TBL] [Abstract][Full Text] [Related]
6. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
[No Abstract] [Full Text] [Related]
7. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
[No Abstract] [Full Text] [Related]
8. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
[No Abstract] [Full Text] [Related]
9. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
Xiong B; Liu X; Zou P; Fan L; Chen W; Li W; Liu L
Leuk Res; 2010 Jul; 34(7):e169-72. PubMed ID: 20122730
[No Abstract] [Full Text] [Related]
10. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
[No Abstract] [Full Text] [Related]
11. Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.
Peñarrubia MJ; Silvestre LA; Conde J; Cantalapiedra A; Garcia Frade LJ
Leuk Res; 2009 Jun; 33(6):e8-9. PubMed ID: 19168219
[No Abstract] [Full Text] [Related]
12. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
Giagounidis AA; Kulasekararaj A; Germing U; Radkowski R; Haase S; Petersen P; Göhring G; Büsche G; Aul C; Mufti GJ; Platzbecker U
Leukemia; 2012 Apr; 26(4):855-8. PubMed ID: 21960245
[No Abstract] [Full Text] [Related]
13. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
Giagounidis AA; Germing U; Strupp C; Hildebrandt B; Heinsch M; Aul C
Ann Hematol; 2005 Sep; 84(9):569-71. PubMed ID: 15891887
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
Takahashi K; Cortes J; Pierce S; Abruzzo L; Kantarjian H; Verstovsek S
Leuk Res; 2013 May; 37(5):552-5. PubMed ID: 23391517
[TBL] [Abstract][Full Text] [Related]
15. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
16. Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome.
Melchert M; Williams C; List A
Leukemia; 2007 Jul; 21(7):1576-8. PubMed ID: 17392815
[No Abstract] [Full Text] [Related]
17. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
18. Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality.
Mesa RA; Hanson CA; Ketterling RP; Schwager S; Knudson RA; Tefferi A
Blood; 2009 Jan; 113(5):1200-1. PubMed ID: 19179475
[No Abstract] [Full Text] [Related]
19. CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.
Ford CD; Asch J; Konopa K; Petersen FB
Bone Marrow Transplant; 2010 Feb; 45(2):403-4. PubMed ID: 19597424
[No Abstract] [Full Text] [Related]
20. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus.
Platzbecker U; Mohr B; von Bonin M; Binder M; Schetelig J; Ehninger G; Bornhäuser M
Leukemia; 2007 Nov; 21(11):2384-5. PubMed ID: 17581611
[No Abstract] [Full Text] [Related]
[Next] [New Search]
